Teva Pharmaceutical Industries Limited reported a 4% increase in revenues, reaching $17.258 billion in 2025, compared to 2024. This growth is attributed to higher revenues from key innovative products such as AUSTEDO, AJOVY, and UZEDY, as well as milestone payments related to the initiation of Phase 3 studies for duvakitug (anti-TL1A). However, this was partially offset by lower revenues from the International Markets segment due to the divestment of its business venture in Japan, decreased sales of certain innovative products across all segments, reduced proceeds from the sale of product rights, and lower generic product revenues in Europe. Exchange rate movements positively impacted revenues by $152 million, net of hedging effects.
The company's financial performance varied across its segments. The United States segment saw a 14% increase in revenues, reaching $9.186 billion, and a 46% increase in profit, amounting to $3.356 billion. In contrast, the Europe segment experienced a 1% decrease in revenues to $5.040 billion and a 17% decrease in profit to $1.303 billion. The International Markets segment also faced challenges, with a 12% decrease in revenues to $2.162 billion and a 24% decrease in profit to $336 million, primarily due to the divestment of its business venture in Japan. Revenues from other activities, mainly the sale of active pharmaceutical ingredients (APIs), decreased by 8% to $870 million.
Operationally, Teva continued to execute its "Pivot to Growth" strategy, focusing on its innovative portfolio and streamlining operations. Research and development expenses, net, increased by 2% to $1.013 billion. The company recorded $1.050 billion in expenses for other asset impairments, restructuring, and other items, and $467 million in legal settlements and loss contingencies. As of December 31, 2025, Teva's debt stood at $16.807 billion, a decrease from $17.783 billion in the previous year.
Looking ahead, Teva anticipates continued growth from its key innovative medicines and biosimilars, as well as successful execution of generic launches. The company expects to expand its innovative medicines and biosimilar pipeline through strategic opportunities. However, Teva also foresees continued competition in the generics market, potentially leading to pricing pressures and lower revenues. The company is actively transforming its business through Teva Transformation programs, which are expected to generate cost savings. Teva is also monitoring macroeconomic headwinds, geopolitical tensions, and supply chain disruptions, which could impact its operations and financial results.
About TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries Limited is a global leader in generic and biosimilar medicines, innovative therapies, OTC products, and active pharmaceutical ingredients. Operating across multiple regions, it offers a broad portfolio in CNS, respiratory, oncology, and other therapeutic areas. The company leverages extensive R&D, manufacturing, and distribution capabilities to deliver high-quality, cost-effective medicines to patients worldwide. Its core focus is on innovation, portfolio optimization, and strategic growth.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.